

Your Invitation to Attend:

Personalized Medicine for Neuropsychiatric Disorders

AN ASSUREX HEALTH PRESENTATION

PRESENTER

LOCATION

TO REGISTER

RSVP

● Dinner will be provided.

GeneSight® is a combinatorial pharmacogenomic test clinically proven to improve medication selection for patients that are affected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar disorder, schizophrenia, acute and chronic pain, ADHD and other behavioral health conditions. Powered by CPGx™, a proprietary combinatorial pharmacogenomics technology, GeneSight measures multiple genomic variants for each patient and weights them together – rather than one at a time – to provide comprehensive genetically driven recommendations for each medication for each patient on an actionable, easy to interpret report. Multiple clinical studies have demonstrated that when GeneSight guided patients' treatment, they were more than twice as likely to respond to selected medications and experienced double the likelihood of remission from their illness compared to current standard of care.^{1,2} GeneSight was developed in the Assurex Health clinical laboratory based on patented technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center, who continue to be research collaborators. In clinical use for over 6 years, GeneSight has more than 14,000 registered healthcare providers, and more than 230,000 patients have undergone GeneSight testing.



6030 S. Mason-Montgomery Road
Mason, OH 45040
866.260.2394

©2016 Assurex Health, Inc.

Assurex and GeneSight are trademarks of Assurex Health, Inc.

All rights reserved. Printed in the U.S.A.



www.genesight.com

1. Hall-Flavin DK, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. *Pharmacogenet Genomics*. 2013 Oct;23(10):535-48. 2. Winner JG, et al. A prospective, randomized double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. *Discov Med*. 2013 Nov;16(89):219-27.